Agios Pharmaceuticals Inc (Agios) discovers and develops investigational medicines for the treatment of cancer and rare genetic metabolic disorders. Its pipeline products include AG-946 a PKR activator that targets hemolytic anemias and sickle cell disease; AG-181 phenylalanine hydroxylase stabilizer that treats phenylketonuria (PKU); mitapivat treats adult pyruvate kinase (PK) deficiency, adult thalassemia, adult sickle cell disease, pediatric PK deficiency, pediatric thalassemia and pediatric sickle cell disease. Agios offers myAgios patient support services program that includes access support, prescription fulfillment, financial assistance, disease education and community connections. The company operates through its subsidiaries in Switzerland, the Netherlands, Germany, Italy and France, among others. Agios is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
88 Sidney Street, Cambridge, Massachusetts, 02139-4169
Website
www.agios.com
Telephone
1 617 6498600
No of Employees
383
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AGIO (NASD)
Revenue (2023)
$26.8M
EPS
XYZ
Market Cap*
$1.7B
Net Profit Margin (2023)
XYZ
19.4%
* As of and is in US$
Agios Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | PYRUKYND |
| AG-946: | myAgios |
| Hemolytic Anemias | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company entered into a worldwide license agreement with Alnylam Pharmaceuticals, Inc. to acquire the rights to develop and commercialize Alnylam’s novel preclinical siRNA targeting TMPRSS6. |
| 2023 | New Products/Services | In February, the company announced the launch of a multi-stakeholder advocacy advisory council for hemolytic anemias including PK deficiency, thalassemia and sickle cell disease. |
| 2022 | New Products/Services | In November, the company along with Almac Group announced the launch of its product PYRUKYND (mitapivat) in the United States. |
Competitor Comparison
| Key Parameters | Agios Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Denmark |
| City | Cambridge | Kenilworth | New York | Princeton | Bagsvaerd |
| State/Province | Massachusetts | New Jersey | New York | New Jersey | - |
| No. of Employees | 383 | 72,000 | 88,000 | 34,100 | 63,370 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jacqualyn A. Fouse, Ph.D. | Chairman | Executive Board | 2022 | 62 |
| Brian Goff | Director; Chief Executive Officer | Executive Board | 2022 | 55 |
| Cecilia Jones | Chief Financial Officer | Senior Management | 2022 | 49 |
| James Burns | Chief Legal Officer | Senior Management | 2022 | 46 |
| Ellen Lopresti | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward